Search Results

You are looking at 91 - 100 of 470 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Sujana Movva, Margaret von Mehren, Eric A. Ross, and Elizabeth Handorf

a meta-analysis of 14 randomized trials of doxorubicin-based adjuvant chemotherapy for STS from a variety of primary sites. There was a benefit for local and distant recurrence-free intervals and overall recurrence-free survival favoring the

Full access

Bryan J. Schneider, Ashish Saxena, and Robert J. Downey

chemotherapy and TRT. Other studies have investigated the role of surgical resection for newly diagnosed LS-SCLC followed by adjuvant chemotherapy. The Japan Clinical Oncology Lung Cancer Study Group evaluated 61 patients with LS-SCLC from 17 centers: 44 had

Full access

Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria

. 22 Furthermore, single-institution retrospective trials magnify the risk of selection bias, making these results difficult for clinicians to apply to a given elderly patient. Role of Adjuvant Chemotherapy Adjuvant chemotherapy after resection

Full access

Margaret Tempero

study by Neoptolemos et al, 3 adjuvant chemotherapy was linked to a significant surgical benefit in this setting, but adjuvant CRT had a “deleterious effect” on survival. “CRT after resection was not a good thing,” she added. However, Dr. Tempero noted

Full access

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

predictive factors? Can certain subsets of premenopausal women with ER-positive tumors be adequately treated using tamoxifen and/or ovarian suppression and forego adjuvant chemotherapy? What is the optimal strategy for using aromatase inhibitors (AIs) in the

Full access

Charles L. Loprinzi and Peter M. Ravdin

References 1 Levine MN Gafni A Markham B . A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer . Ann Intern Med 1992 ; 117 : 53 – 58 . 2 Whelan T. Levine M

Full access

Margaret Tempero

for recurrence. The TAILORx study was designed to validate the use of the test in patients with early-stage breast cancer at intermediate risk for recurrence. Based on its findings, 70% of these patients can safely avoid adjuvant chemotherapy. This

Full access

Jill A. Foster, Maziar Abdolrasulnia, Hamidreza Doroodchi, Joan McClure, and Linda Casebeer

. 5 Griggs JJ Culakova E Sorbero MF . Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens . J Clin Oncol 2007 : 25 : 2522 – 2527 . 6 Landercasper J Dietrich LL Johnson JM . A breast center

Full access

Early-Stage Breast Cancer Expiration Date: 2/18/14 CASE REPORT: Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations Expiration

Full access

Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin

reduced the local recurrence rate to 5% to 8% when combined with neoadjuvant chemoradiation and adjuvant chemotherapy. 5 , 6 Efforts to improve the current neoadjuvant standard of LARC through integrating newer chemotherapy or molecularly targeted agents